Exenatide Reduces Urinary Transforming Growth Factor-β1 and Type IV Collagen Excretion in Patients with Type 2 Diabetes and Microalbuminuria

Kidney and Blood Pressure Research, 06/08/2012

The results indicate that exenatide reduces urinary transforming growth factor–β1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria, which may be partly contributory to its directly renoprotective role.

Author Commentary

The article showed exenatide reduces urinary transforming growth factor–?1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria, which may be partly contributory to its directly renoprotective role. The results is intresting. However, the sample size is small. therefore, further large sample studies are needed.

Follow This Author View Author Commentary Page
Print Article Summary Cat 2 CME Report